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Viral infections are often the etiological agents of severe acute and chronic human diseases. Their peculiar
biology usually leads to the need of design speciﬁc therapies for each virus, and the eradication of the
viruses and the healing of the patients very often are not reached also after decades of theoretical and
applied researches. HIV is a classical example of how the efforts of the researchers may be disappointed
in eradicating a virus infection in an infected patient. Here I present a hypothesis for a new antiviral
approach that may be suitable for the treatment of HIV infected patients. The same approach, with oppor-
tune modiﬁcations, may be also applied as healing strategy for a wide set of viruses infections. In brief,
my idea is to use the retrotranscription machinery and the packaging system of HIV infected cells to
amplify the interfering effects of siRNAs directed against HIV genes and transcripts. The coding sequences
for the interfering RNAs are brought to the infected cells via modiﬁed HIV virions deﬁcient for structural
viral genes that will use the resident viral activities of HIV infected cell as helpers. The use of this strategy
will probably lead to an intracellular, intercellular and systemic ampliﬁcation of the speciﬁc virus-tar-
geted interfering activities. Moreover this strategy may show novel levels of interference: a competition
between the deﬁcient and wild type viruses for the packaging molecules and the possibility of homolo-
gous recombination between the deﬁcient and wild type viruses that may lead in turn to the formation of
recombinant non infectious viruses, and the removing of wild type provirus sequence from the host gen-
ome of infected cells by recombination.
 2012 Elsevier Ltd. All rights reserved.Introduction
Since the discovery of HIV, several approaches have been at-
tempted to control or eradicate the HIV infection. Strategies span
from antiretroviral approaches, drug targeted therapies, aptamers,
gene therapy on precursor cells, HIV-speciﬁc siRNAs, ribozymes
and many others. Unluckily, no efﬁcient way to eradicate HIV from
infected individuals has been still developed [1].
The most common strategy used nowadays is a drug cocktail
that speciﬁcally inhibits several key steps of the viral life cycle in
a therapeutic regimen called HAART. Unluckily, HAART treated pa-
tients usually have to follow the protocol for their entire life with
no eradication of the disease, severe chronic toxic effects and high
expenses either for the community or for the patient [1].
The need to develop a very efﬁcient way to control or eradicate
HIV is still urgent. It is true that many steps have been taken to-
wards a therapy, but HIV still is a step ahead of the researches.
One of the reasons of this phenomenon is the low ﬁdelity of HIV re-
verse transcriptase that allows HIV to evolve at a very high rate [1].
Several strategies take advantage from RNA interference medi-
ated gene silencing or translating inhibition operated by siRNAs
and miRNAs and related molecules. RNA mediated interferencell rights reserved.has key regulatory functions in many cellular processes, such as
differentiation, development, and metabolism [2–4], but also dur-
ing virus infection. The possibility of using multiple siRNAs to
interfere and inhibit speciﬁc HIV functions has many charming
characteristics, ﬁrst of all the possibility to bypass the capacity of
HIV to escape from therapies taking advantage from its high evolu-
tionary rate. This is why many efforts are taken from the research-
ers to design efﬁcient HIV targeted siRNAs and, most of all, to
design efﬁcient vectors for the delivery of molecules speciﬁcally
to infected or infectable cells, to design respectively a healing or
a protective strategy [5].
HIV, and other lentiviruses, have also had a great impact in re-
search thanks to their unique features. HIV derived vectors are
used commonly as very efﬁcient transgenes vectors. They show
high rate of gene transfer and the capacity of integration into the
host genome (a key characteristic of retroviral vectors), differently
from episomial viruses based vectors [6]; moreover they show the
ability to establish a long lasting transgene expression. Lentiviruses
derived vectors also show a bias in the integration on introns of
highly expressed genes, avoiding the oncogenic potential of the
promoter biased vectors. Another big advantage of lentivirus de-
rived vectors is their ability to infect both dividing and not dividing
cells and potentially a wide spectrum of cell type, due to the vector
design. Finally, HIV derived vectors usually can carry up to 7 Kbs or
more without losing their infectious capacity. For a very good
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refer to Pluta et Kacprzac [7].
RNA interference (RNAi) is now considered as a powerful tool to
negatively regulate gene expression in almost any eukarya. Its
pathway is still under intense study and details of its biological
and molecular mechanism of action have been described else-
where [8,9]. In brief, long dsRNA (double stranded RNA) molecules
are cleaved by the endonuclease Dicer into short 20–30 (with a
bias of 21–25) nucleotide small interfering RNAs (siRNAs) which
are in turn incorporated into a RISC (RNA induced silencing com-
plex). RISC is a multi-proteic complex that selectively degrades
mRNAs that share sequence homology with the siRNA loaded in
the RISC, with a bias with the sequence homology in the 3’UTR of
the transcript, even if this is not a rule. In mammalian systems,
and so in humans, siRNAs can be delivered per se externally using
several strategies, such as RNA electroporation, or expressed
endogenously as long precursors (to be later cleaved) from pol III
promoters (these precursors are called short hairpin RNAs or
shRNAs) or from pol II promoters (as long precursors that will be
cleaved into micro RNAs or miRNAs, or miRs), that will result into
speciﬁc downregulation of target mRNAs [10–13] and sometimes
into the silencing of genomic loci that share sequence homology
with the interfering RNA molecules.The hypothesis
The strategy here suggested is to use in vitro assembled HIV de-
rived lentivirus vectors to deliver in vivo speciﬁc anti-HIV mole-
cules; speciﬁcally here I suggest to use vectors able to induce the
transcription of shRNAs and the generation of siRNAs against HIV
speciﬁc transcripts.
These in vitro assembled vectors must be deﬁcient for structural
viral genes (e.g. gag, pol and env) but must retain the recognition
sequences to be retrotranscribed, packed (LTRs and Psi sequences),
and to have the transducted sequences transcribed. Many commer-
cial vectors share these characteristics [14].
From now on, the so designed vectors will be called H-Virions
when packed, H-Vectors when I will refer to the RNA vectors,
and H-proviruses when I will refer to the retrotranscribed and inte-
grated vector. ‘‘H’’ is for Healing. Wt-(Wild type) Virions, Viruses,
Proviruses, transcript et cetera will be used to indicate respectively
infective HIV Virions, Viruses, Proviruses, transcript et cetera that
can be found in the population.
The shRNA sequences transducted by H-Vectors and related siR-
NAs are to be designed to target speciﬁc wt-HIV genes and tran-
scripts, such as Gag, Pol, Env or Tat, Rev and Nef genes and their
transcripts; a very good review about possible shRNAs with these
characteristics can be found in Mcintyre et al. [15]. Speciﬁcally, it
seems that the early transcribed Tat, Rev and Nef genes [16] could
be good candidates to be used to interfere with HIV infection [17].
The use of this strategy could lead to several advantages when
used in vivo in wt-HIV infected patients.
1. The H-Virions will infect the same cells that are potential
targets of wt-HIV virions. There will be no H-Virions inter-
nalization in cells that are not potentially targeted by wt-
HIV virions.
2. Several strategies to target speciﬁcally HIV-infected cells in
the contest of an infected organismhave been described else-
where [18–21]; the possibility to target the H-Virions or the
H-Vectors speciﬁcally towards HIV-infected cells may help
to enhance the safety of the approach here described.
3. If the H-Virion infects a cell that is not a wt-HIV infected cell,
the vector will be reasonably retained for a certain degree of
time inside the cell and, due to a possible latter infectionfrom wt-HIV, will be activated and assert its functions, con-
ferring a mild protective activity against a productive wt-
HIV infection.
4. Instead, if the sequences born by the H-Vector will be retro-
transcribed and integrated into the host genome by the
enzymatic activities brought inside the H-Virions, the pro-
tecting activity could be even greater.
5. Instead, if the H-Virion infects a cell that is yet been infected
by a wt-HIV, the wt-HIV will function as a perfect helper for
the healing capacity of H-virions. These cells will be called
co-infected cells (CICs). Speciﬁc targeting of H-Virions
towards HIV-infected cells [18–21] may help to increase
the CICs numbers after administration, enhancing efﬁcacy
and safety.
6. In CICs, H-proviruses will actively transcribe shRNAs, and
the wt-HIV speciﬁc siRNAs will lead to a decreased activity
of wt-HIV functions and infectivity. The capacity to design
H-vectors able to produce multiply siRNAs could lead to an
interfering activity against several wt HIV transcripts, broad-
ening the capacity of H-Vectors to interfere with wt-HIV
functions. Moreover, due to the multiple siRNAs production
and their short length, H-Vectors could easily avoid the
escaping mechanisms of wt-HIV thanks to the high error
rate of retrotransciptase and the subsequent high rate of
mutations. H-Vectors could easily target many wt-HIV vari-
ants, also those newly generated in the patient during the
wt-HIV infection.
7. In CICs, the H-vectors will interfere with wt-HIV acting as
quencher of wt-HIV targeted machineries, lowering the
activity of wt-HIV.
8. In CICs, H-vectors will interfere with wt-HIV packaging sys-
tem, so a certain degree of virions produced by CICs will be
H-Virions instead of wt-HIV virions.
9. There is the possibility that in CICs, H-Provirus and wt-HIV
provirus could recombine by homologous recombination
leading to the disruption of wt-HIV provirus and thus either
eradicate the infection from those cells or leading to chro-
mosomal rearrangements that could lead to cell death.
10. There is the possibility that in CICs, H-Provirus and wt-HIV
provirus could recombine, leading to the creation of deﬁ-
ciency viruses, not able to induce an effective wt-HIV infec-
tion but still retaining part of the siRNA activity and thus
maintaining the protective function. Even if some infective
HIV virions could be produced by these events of recombina-
tion, probably they will act as self-limiting viruses because
they would have incorporated self-targeting siRNAs.
11. Remarkably, the H-Virions produced by CICs could amplify
intercellulary and systemically the spreading of H-virions
and their healing and protective activity. So, theoretically,
just a single dose treatment could lead to the protective,
therapeutic and possibly healing capacity of H-Virions.
12. H-Virions will share many surface epitopes with wt-Virions,
so they may enhance the normal host immune response
against the pathogen.
Evaluation of the hypothesis
The use of HIV derived lentivirus vectors as an effective way to
transfer genetic material and as tool in research on mammal sys-
tems are established data. Many HIV derived lentivirus vectors
are now commercially available and are used in many laboratory
routine techniques as routine expression vectors [14]. The innova-
tive proposal of the present hypothesis is to transfer the knowledge
and expertise from the laboratory to the therapy; to transform a re-
search tool to a healing strategy to be used in vivo in patients. The
use of shRNAs and siRNAs to modulate the transcriptome output
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use of shRNAs and siRNAs as therapeutic effectors has been widely
postulated and partially used in many human diseases, and HIV
makes no exception [15]. The innovative approach of the present
hypothesis is to combine the siRNA technology with viral vectors
derived from the same disease that is to be cured, assuring host cell
speciﬁcity, many degrees of interference with viral infection both
intracellularly and systemically, as an ampliﬁcation of the healing
molecules intracellularly and of the healing vectors systemically,
and a possible protection for non infected cells. Moreover, in the-
ory, a one dose or few doses treatment with almost no side effects
would be effective. It should be tested if the sequences born by the
H-Vectors should be put under the control of viral promoters (to
enhance the interfering capacity of the H-Vectors and the speciﬁc-
ity of the response in CICs) or host promoters (to enhance the pro-
tective effect in non wt-HIV infected cells, but with the risk to
increase potential side effects). In vivo and in vitro data are needed
to conﬁrm or confute the hypothesis, but in the belief of the author
the hypothesis is worth to be investigated.Discussion
The hypothesis is about the combination of accepted molecular
mechanisms and used technologies, bringing a research tool such
as HIV-derived lentiviral vectors into therapy. The prediction of
the impact of the therapy here described is difﬁcult to formulate,
but reasonably it could lead from an attenuation of the symptoms
to a complete eradication of the disease. Of course the variables are
many, from the serotype of the patient, the personal response to
the therapy, the stage of the disease at which the therapy is admin-
istrated, to the speciﬁc design of the vector and the previous treat-
ments born by the patients, especially the antiretroviral therapies
now broadly uses in the HAART cocktail.
Interestingly, the strategy here presented could be combined
with immunotherapeutic strategies, where stimulated T cells are
targeted to infected cells with the aim to eradicate the infection
[17,22]. The strategy here described could limit the HIV spread,
while via immunotherapeutic strategies infected cells could be
eradicated. Please note that while CICs should have their ability
to produce infective virions severely impaired or even stopped,
they can be still recognized by the immune system as infected
cells.
Another potential risk of a so designed therapy may reside in
the possibility of transferring the H-Virions from a treated patient
to another person by unprotected sexual intercourse or blood con-
tamination, as it may happen in the habit of sharing needles in
endovenous drug administration in many drug-addicted commu-
nities. I really think that the risk to share H-Virions together with
infective wt-HIV virions is a well balanced risk, that in theory
may also have an epidemiologically positive effect into the possi-
bility of eradicate the HIV infection from the population, especially
in areas where traditional administration of therapy may result
difﬁcult. Of course this approach raises serious ethical consider-
ations. Another weak point of the theory is that a so designed treat-
ment could lead to a co-evolution of the H- and wt-Virions inside
the patients, but the use of multiple shRNAs in the H-Vectors
should minimize the related risks.
Advantages of the method could of course be great, from the
relatively easiness of the massive production of H-Vectors, to the
possibility of one or few dose therapy approach, to the possibility
to design speciﬁc H-Vectors ad hoc for each serotype, to the possi-
bility to administrate a cocktail of several H-Vectors to the same
patient and so on; the H-Vector strategy seems to be potentially
a very ﬂexible tool.If the hypothesis will be conﬁrmed, the H-Vectors should work
both intracellularly and systemically. H-Vectors should protect non
infected cells from further infection and in CICs they should inter-
fere with HIV functions at many levels: they should stop or lower
the production of viral factors via siRNAs and drain the remaining
viral factors for their own metabolism, acting as a ‘‘virus of the
virus’’. So the infected cells should survive longer and the non in-
fected cells should have a sort of protection from the infection.
Moreover, the CICs where the RNA interference is not able to stop
the production of viral factors, will produce together with the wt-
Virions also H-Virions, allowing a systemic spread of the H-Vectors
with their healing and/or protective activities. Moreover, the ratio
between infective vs non infective virions should decrease, allow-
ing the residual immune system of the host to built up a more efﬁ-
cient immune response to the pathogen, maybe in combination
with an immunotherapeutic strategy, as described. In the best sce-
nario the H-Strategy should be able to eradicate the infection, in a
milder scenario, the H-Strategy should stop the progression of the
disease, improve the patients’ conditions with almost no side
effects.
If the strategy here described should be effective as expected,
the same rationale might be used as healing strategy or in combi-
nation with other approaches for several diseases of viral origin
that still escape traditional therapies, such as the widespread HCV.
The use of virus-X derived deﬁciency vectors able to produce
speciﬁc siRNAs against key components of the virus-X metabolism
might became in the future a new antiviral approach, because
these healing viruses will have the same host spectrum, will specif-
ically interfere with the virus functions in the co-infected cells and
may manifest a protective effect in non infected cells.Conﬂict of interest statement
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